Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
68.33 (1y: +22%)
Market Cap 1.26 B P/E(ttm) 14.40
Enterprise Value 1.36 B P/B 2.90
CHE- NYSE (USA)
Chemed Corporation
  • Currently 2.5/5
Business Predictability Rank: 2.5-Star
Back Testing Results:
Average gain of all 2.5-Star stocks: 7.3% per year.
% of Stocks that are in still loss if held for 10yrs: 18%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$68.33
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry		 vs
history
Cash to Debt 0.398
CHE's Cash to Debt is ranked higher than
57% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 0.32 vs. CHE: 0.398 )
CHE' s 10-Year Cash to Debt Range
Min: 0.02   Max: 1.92
Current: 0.4
0.02
1.92
Equity to Asset -0.081
CHE's Equity to Asset is ranked lower than
75% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 0.26 vs. CHE: -0.081 )
CHE' s 10-Year Equity to Asset Range
Min: -0.22   Max: 0.26
Current: -0.08
-0.22
0.26
Interest Coverage 11.2
CHE's Interest Coverage is ranked higher than
56% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 7.80 vs. CHE: 11.2 )
CHE' s 10-Year Interest Coverage Range
Min: 3   Max: 25
Current: 11.2
3
25
F-Score: 7
Z-Score: 5.01
M-Score: -2.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry		 vs
history
Operating margin (%) 10.90
CHE's Operating margin (%) is ranked higher than
69% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 7.30 vs. CHE: 10.90 )
CHE' s 10-Year Operating margin (%) Range
Min: -2.5   Max: 11.6
Current: 10.9
-2.5
11.6
Net-margin (%) 6.2
CHE's Net-margin (%) is ranked higher than
64% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 3.85 vs. CHE: 6.2 )
CHE' s 10-Year Net-margin (%) Range
Min: -2.2   Max: 6.4
Current: 6.2
-2.2
6.4
ROE (%) 19.7
CHE's ROE (%) is ranked higher than
76% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 11.20 vs. CHE: 19.7 )
CHE' s 10-Year ROE (%) Range
Min: -4.7   Max: 20.8
Current: 19.7
-4.7
20.8
ROA (%) 10.4
CHE's ROA (%) is ranked higher than
79% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 4.60 vs. CHE: 10.4 )
CHE' s 10-Year ROA (%) Range
Min: -2.6   Max: 10.8
Current: 10.4
-2.6
10.8
ROC (Joel Greenblatt) (%) 247.30
CHE's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 17.40 vs. CHE: 247.30 )
CHE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -22.8   Max: 503
Current: 247.3
-22.8
503
Revenue Growth (%) 9
CHE's Revenue Growth (%) is ranked higher than
83% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 4.50 vs. CHE: 9 )
CHE' s 10-Year Revenue Growth (%) Range
Min: -10.5   Max: 25.2
Current: 9
-10.5
25.2
EBITDA Growth (%) 9.3
CHE's EBITDA Growth (%) is ranked higher than
78% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 4.70 vs. CHE: 9.3 )
CHE' s 10-Year EBITDA Growth (%) Range
Min: -44.6   Max: 107.6
Current: 9.3
-44.6
107.6
EPS Growth (%) 9.3
CHE's EPS Growth (%) is ranked higher than
74% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 7.70 vs. CHE: 9.3 )
CHE' s 10-Year EPS Growth (%) Range
Min: 7.8   Max: 23
Current: 9.3
7.8
23
» CHE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

CHE Guru Trades in Q2 2012

John Keeley 17,240 sh (+45.36%)
Joel Greenblatt 94,353 sh (+11.6%)
Mario Gabelli 780,195 sh (+9.93%)
Chuck Royce 2,130,840 sh (+4.44%)
Jim Simons Sold Out
» More
Q3 2012

CHE Guru Trades in Q3 2012

John Keeley 19,440 sh (+12.76%)
Joel Greenblatt 94,778 sh (+0.45%)
Mario Gabelli 776,295 sh (-0.5%)
Chuck Royce 1,959,070 sh (-8.06%)
» More
Q4 2012

CHE Guru Trades in Q4 2012

Mario Gabelli 776,845 sh (+0.07%)
Joel Greenblatt 94,402 sh (-0.4%)
John Keeley 18,609 sh (-4.27%)
Chuck Royce 1,823,098 sh (-6.94%)
» More
Q1 2013

CHE Guru Trades in Q1 2013

Jim Simons 16,900 sh (New)
John Keeley 19,440 sh (+4.47%)
Mario Gabelli 777,320 sh (+0.06%)
Joel Greenblatt 89,155 sh (-5.56%)
Chuck Royce 1,422,242 sh (-21.99%)
» More
» Details

Insider Trades

Latest Guru Trades with CHE

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Keeley 2012-06-30 Add 45.36%0.01%$54.78 - $64.06 $ 68.3315%17240
Joel Greenblatt 2012-03-31 Add 41.49%0.13%$51.18 - $63.87 $ 68.3325%84545
Ron Baron 2012-03-31 Sold Out 0.12%$51.18 - $63.87 $ 68.3325%0
John Keeley 2012-03-31 Add 44.81%$51.18 - $63.87 $ 68.3325%11860
Joel Greenblatt 2011-12-31 Add 110.65%0.19%$48.24 - $60.68 $ 68.3328%59753
Ron Baron 2011-12-31 Reduce -50.18%0.14%$48.24 - $60.68 $ 68.3328%371627
John Keeley 2011-12-31 New Buy0.01%$48.24 - $60.68 $ 68.3328%8190
Joel Greenblatt 2011-09-30 Add 131.33%0.14%$50.64 - $67.08 $ 68.3316%28366
Joel Greenblatt 2011-06-30 Add 65.9%0.04%$63.94 - $72.02 $ 68.331%12262
Joel Greenblatt 2011-03-31 New Buy0.15%$61.96 - $66.71 $ 68.337%7391
Mario Gabelli 2011-03-31 Reduce -25.49%0.12%$61.96 - $66.71 $ 68.337%715875
Jean-Marie Eveillard 2011-03-31 Sold Out $61.96 - $66.71 $ 68.337%0
Jean-Marie Eveillard 2010-12-31 Reduce -50.03%0.06%$55.41 - $64.66 $ 68.3313%166500
Jean-Marie Eveillard 2010-06-30 Reduce -29.95%0.04%$51.31 - $58.34 $ 68.3322%333230
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/E(ttm) 14.40
CHE's P/E(ttm) is ranked higher than
65% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 16.20 vs. CHE: 14.40 )
CHE' s 10-Year P/E(ttm) Range
Min: 10.57   Max: 41.7
Current: 14.4
10.57
41.7
P/B 2.90
CHE's P/B is ranked lower than
72% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 1.99 vs. CHE: 2.90 )
CHE' s 10-Year P/B Range
Min: 1.21   Max: 5.32
Current: 2.9
1.21
5.32
P/S 0.91
CHE's P/S is ranked lower than
57% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 0.81 vs. CHE: 0.91 )
CHE' s 10-Year P/S Range
Min: 0.56   Max: 2.08
Current: 0.91
0.56
2.08
PFCF 13.00
CHE's PFCF is ranked higher than
58% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 14.34 vs. CHE: 13.00 )
CHE' s 10-Year PFCF Range
Min: 7.11   Max: 141.48
Current: 13
7.11
141.48
EV-to-EBIT 8.5
CHE's EV-to-EBIT is ranked higher than
80% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 13.20 vs. CHE: 8.5 )
CHE' s 10-Year EV-to-EBIT Range
Min: 6.9   Max: 190.2
Current: 8.5
6.9
190.2
PEG 1.5
CHE's PEG is ranked higher than
92% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 1.30 vs. CHE: 1.5 )
CHE' s 10-Year PEG Range
Min: 0.1   Max: 8.13
Current: 1.5
0.1
8.13
Shiller P/E 17.8
CHE's Shiller P/E is ranked higher than
73% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 11.50 vs. CHE: 17.8 )
CHE' s 10-Year Shiller P/E Range
Min: 15.59   Max: 128.41
Current: 17.8
15.59
128.41

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 1.02
CHE's Dividend Yield is ranked higher than
69% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 1.85 vs. CHE: 1.02 )
CHE' s 10-Year Dividend Yield Range
Min: 0.35   Max: 5.98
Current: 1.02
0.35
5.98
Dividend Payout 0.1479
CHE's Dividend Payout is ranked higher than
97% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 0.75 vs. CHE: 0.1479 )
CHE' s 10-Year Dividend Payout Range
Min: 0.08   Max: 1.13
Current: 0.15
0.08
1.13
Dividend growth (3y) 17.2
CHE's Dividend growth (3y) is ranked higher than
99% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: -6.00 vs. CHE: 17.2 )
CHE' s 10-Year Dividend growth (3y) Range
Min: -32.1   Max: 25.7
Current: 17.2
-32.1
25.7
Yield on cost (5-Year) 3.66
CHE's Yield on cost (5-Year) is ranked higher than
87% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 2.00 vs. CHE: 3.66 )
CHE' s 10-Year Yield on cost (5-Year) Range
Min: 1.28   Max: 21.86
Current: 3.66
1.28
21.86
Share Buyback Rate 4
CHE's Share Buyback Rate is ranked higher than
95% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: -0.60 vs. CHE: 4 )
CHE' s 10-Year Share Buyback Rate Range
Min: 4   Max: -7.7
Current: 4

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 22.6
CHE's Price/Net Current Asset Value is ranked higher than
84% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 6.55 vs. CHE: 22.6 )
CHE' s 10-Year Price/Net Current Asset Value Range
Min: 9.3   Max: 46.1
Current: 22.6
9.3
46.1
Price/DCF (Projected) 0.8
CHE's Price/DCF (Projected) is ranked higher than
81% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 0.80 vs. CHE: 0.8 )
CHE' s 10-Year Price/DCF (Projected) Range
Min: 0.6   Max: 2.1
Current: 0.8
0.6
2.1
Price/Median PS Value 0.9
CHE's Price/Median PS Value is ranked higher than
61% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 0.90 vs. CHE: 0.9 )
CHE' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 1.5
Current: 0.9
0.7
1.5
Price/Peter Lynch Fair Value 1.5
CHE's Price/Peter Lynch Fair Value is ranked higher than
97% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 1.10 vs. CHE: 1.5 )
CHE' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.5   Max: 7.1
Current: 1.5
0.5
7.1
Earnings Yield (Greenblatt) 11.80
CHE's Earnings Yield (Greenblatt) is ranked higher than
80% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 8.50 vs. CHE: 11.80 )
CHE' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 14.5
Current: 11.8
0.5
14.5
Forward Rate of Return (Yacktman) 15.67
CHE's Forward Rate of Return (Yacktman) is ranked higher than
83% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 11.99 vs. CHE: 15.67 )
CHE' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -43.2   Max: 126.6
Current: 15.67
-43.2
126.6

Business Description

Chemed Corporation was incorporated in Delaware in 1970 as a subsidiary of W. R. Grace & Co. and succeeded to the business of W. R. Grace & Co.'s Specialty Products Group as of April 30, 1971 and remained a subsidiary of W. R. Grace & Co. until March 10, 1982. The Company operates through its two wholly owned subsidiaries: VITAS Healthcare Corporation or VITAS and Roto-Rooter Group, Inc. or Roto-Rooter. During 2009 the Company conducted its business operations in two segments: Vitas Group or Vitas and the Roto-Rooter Group or Roto-Rooter. The VITAS segment provides hospice services for patients with severe, life-limiting illnesses. This type of care is aimed at making the terminally ill patient's end of life as comfortable and pain-free as possible. Hospice care is typically available to patients who have been initially certified or re-certified as terminally ill by their attending physician, if any, and the hospice physician. VITAS offer all levels of hospice care in a given market, including routine home care, inpatient care and continuous care. Over 90% of VITAS' revenues are derived through Medicare and Medicaid reimbursement programs. The Roto-Rooter segment provides repair and maintenance services to residential and commercial accounts using the Roto-Rooter registered service mark. Such services include plumbing and sewer, drain and pipe cleaning. They are delivered through company-owned and operated territories, independent contractor-operated territories and franchised locations. This segment also manufactures and sells products and equipment used to provide such services. The principal raw materials needed for the Company's manufacturing operations are purchased from United States sources. Vitas also competes with a number of national and regional hospice providers, including Odyssey Healthcare, Inc., hospitals, nursing homes, home health agencies and other health care providers. The Company is subject to federal and state regulation.
Company Website
SEC Reports
Industry: Medical Care
Compare:FMS, DVA, FSNUY, BDUUF, SKHCY
Traded in other countries:CXM.Germany
» More Articles for CHE

Headlines

Articles On GuruFocus.com
Chemed Corporation: Fundamental Stock Research Analysis Jan 29 2013 
The Best Stocks With Dividend Growth From Last Week (August 06 – August 12, 2012) Aug 12 2012 
12 Healthcare Dividend Stocks With Highest Short Float Ratio Jun 02 2012 
Stocks Mario Gabelli Keeps Buying - One That Paulson Likes Too Jan 23 2012 
9 Dividend Stocks Raising Their Yield On Cost Aug 15 2011 
Guru Stocks Raising Dividends: THO, ACU, KAMN, PRIM, CHE Aug 15 2011 
11 Cheapest Healthcare Dividend Stocks to Consider Aug 02 2011 
Chemed Corp. Reports Operating Results (10-K) Feb 28 2011 
Chemed Corp. Reports Operating Results (10-Q) Nov 03 2010 
Chemed Corp. Reports Operating Results (10-Q) Jul 30 2010 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial